The Ets transcription factor PU.1 is a hematopoietic master regulator essential for the development of myeloid and B-cell lineages. As we previously reported, PU.1 sometimes represses transcription on forming a complex with mSin3A-histone deacetyl transferase-MeCP2. Here, we show an interaction between PU.1 and DNA methyltransferases, DNA methyltransferase (Dnmt)3a and Dnmt3b (Dnmt3s). Glutathione-S-transferase pulldown assay revealed that PU.1 directly interacted with the ATRX domain of Dnmt3s through the ETS domain. Dnmt3s repressed the transcriptional activity of PU.1 on a reporter construct with trimerized PU.1-binding sites. The repression was recovered by addition of 5-aza-deoxycitidine, a DNA methyltransferase inhibitor, but not trichostatin A, a histone deacetylase inhibitor. Bisulfite sequence analysis revealed that several CpG sites in the promoter region neighboring the PU.1-binding sites were methylated when Dnmt3s were coexpressed with PU.1. We also showed that the CpG sites in the p16 INK4A promoter were methylated by overexpression of PU.1 in NIH3T3 cells, accompanied by a downregulation of p16 INK4A gene expression. These results suggest that PU.1 may downregulate its target genes through an epigenetic modification such as DNA methylation.
Introduction
PU.1 was identified as the gene encoding the protein that binds to a purine-rich sequence (PU box) in the promoter region of the mouse major histocompatibility complex (MHC) class II I-Ab gene (Klemsz et al., 1990) . The gene is identical to the spi-1 oncogene originally isolated from proviral integration sites in Friend virusinduced mouse erythroleukemia (Moreau-Gachelin et al., 1989) . In normal hematopoiesis, the expression of PU.1 is upregulated in B cells and myelomonocytic lineages, but downregulated in T cells and erythroid cells. PU.1 encodes a transcription factor that belongs to the Ets family and controls the expression of many Bcell-and macrophage-specific genes, including the immunoglobulin genes and the macrophage colony stimulation factor receptor (M-CSFR) gene (MoreauGachelin, 1994; Tenen et al., 1997; Oikawa et al., 1999) . Furthermore, sustained expression of PU.1 in erythroblasts is believed to contribute to the blocking of erythroid differentiation, as we and others have reported (Rao et al., 1997; Yamada et al., 1997) .
PU.1 functions in concert with other transcription factors and cofactors, including c-Myb, C/EBPa (Oelgeschlager et al., 1996) , NF-IL-6 (C/EBPd) (Nagulapalli et al., 1995) , NF-EM-5/Pip (Eisenbeis et al., 1995) , cFos (Bassuk and Leiden, 1995) , c-Jun (Pongubala and Atchison, 1997) , Rb (Konishi et al., 1999) and RUNX1/ AML1 (Zhang et al., 1994) . We have previously reported that PU.1 interacts with CRE-binding protein (CBP) or p300, which functions as a coactivator for several transcription factors . We have also demonstrated that PU.1 binds to the corepressor mSin3A and forms a complex with histone deacetyl transferase (HDAC)1 (Kihara-Negishi et al., 2001) . Moreover, we have reported that MeCP2 is a binding partner of the PU.1-mSin3A-HDAC complex, but not of the PU.1-CBP complex (Suzuki et al., 2003) .
DNA methylation, the major epigenetic modification of vertebrate genomes, is a key mechanism for silencing gene expression (Ng and Bird, 1999) . It is documented that the methylation of CpG islands is associated with changes in chromatin structure and the repression of gene transcription (Robertson, 2002) . Many studies have also revealed that aberrant DNA methylation in tumor suppressor genes such as p16/INK4a, p19/ARF and p21/WAF1 are early events in the process of tumorigenesis (Robertson, 2001) . DNA methylation is catalysed by the activation of several DNA methyltransferases (Dnmts) during cell replication. There are at least three different major catalytically active Dnmts, Dnmt1 (Bestor et al., 1988) , Dnmt3a and Dnmt3b (Okano et al., 1998) , which are involved in cellular DNA methylation. In somatic cells, Dnmt1 has the maintenance methyltransferase activity as a consequence of its affinity for hemimethylated DNA. Dnmt3a and Dnmt3b (Dnmt3s) are de novo DNA methyltransferases equally effective in the methylation of hemimethylated and unmethylated DNA. DNA methylation and histone deacetylation may work in concert to silence gene expression (Bird and Wolffe, 1999) . In fact, Dnmt3s form a complex with Sin3A-HDAC and are involved in transcriptional repression as corepressors.
In this study, we examined interactions between PU.1 and Dnmt3a or Dnmt3b. We found that the interaction is associated with PU.1-mediated DNA methylation to repress gene expression, suggesting that PU.1 is involved in site-specific epigenetic modifications.
Results
Physical interaction between PU.1 and Dnmt3a/b We previously reported that MeCP2 interacts with, and acts as a corepressor for, PU.1 probably by facilitating the formation of a complex with mSin3A and HDACs (Suzuki et al., 2003) . There is growing evidence to suggest that Dnmt1 interacts with the methylated DNAbinding protein (MBD) family (Tatematsu et al., 2000) and that Dnmt3s mediate the binding of MBD family members such as MeCP2 to methylated CpG sites (Majumder et al., 2002) . Therefore, there is a possibility that PU.1 could form a complex with Dnmt3a and Dnmt3b. In order to test this possibility, we first carried out a coimmunoprecipitation assay. Murine hematopoietic progenitor (stem cell antigen-1 positive (Sca-1 þ )) cells from the bone marrow and their lysates were prepared for the assay. As shown in Figure 1a , only an antibody (Ab) against PU.1 co-precipitated Dnmt3s with PU.1 (Figure 1a) , suggesting that PU.1 and Dnmt3s associate in vivo. To investigate whether PU.1 interacts directly with Dnmt3s, we then performed a glutathione-S-transferase (GST) pulldown assay. The 35 S-labeled Dnmt3a and Dnmt3b translated in vitro bound to GST-PU.1 fusion protein (Figure 1b) . The 35 Slabeled in vitro translated CBP 1890 (1283-1915 amino acids (a.a.)) and MeCP2 used as positive controls bound to GST-PU.1, consistent with our previous reports Suzuki et al., 2003) , while the 35 S-labeled luciferase used as a negative control did not bind to GST-PU.1. These results suggest that the interaction between PU.1 and Dnmt3s is direct.
To determine the region of PU.1 required for interaction with Dnmt3a and Dnmt3b, various deleted forms of GST-PU.1 fusion proteins were used ( Figure 2a ). As shown in Figure 2b , the 35 S-labeled FLAG-tagged Dnmt3a translated in vitro (IVTDnmt3a) bound to the wild-type PU.1 (GST-PU.1 WT), PU.1 with a deletion of the activation domain (GST-PU.1 DA), and PU.1 having only the Ets domain (GST-PU.1 Ets), while it did not bind to PU.1 deleted of the Ets domain (GST-PU.1 DE). Similar results were obtained when 35 S-labeled FLAG-tagged Dnmt3b translated in vitro (IVT-Dnmt3b) was used instead of IVT-Dnmt3a. These results indicate that the Ets domain of PU.1 is sufficient for the interaction with Dnmt3a and Dnmt3b.
We next performed a GST pulldown assay using deletion forms of GST-Dnmt3a and GST-Dnmt3b fusion proteins with 35 S-labeled in vitro translated PU.1 to identify the region of Dnmt3s necessary for binding to PU.1 (Figure 2c ). PU.1 bound to the wildtype Dnmt3a and Dnmt3b (GST-3a WT and GST-3b WT), and Dnmt3a and Dnmt3b having the ATRX domain (GST-3a ATRX and GST-3b ATRX), but not to those having the amino-terminal region , or the carboxy-terminal region having the catalytic domain (GST-3a C and GST-3b C) (Figure 2d ). These results indicate that the region containing the ATRX domain of Dnmt3a and Dnmt3b is necessary for the interaction with PU.1.
Coexistence with Dnmt3s and HDAC1-mSin3A-PU.1 complex We previously reported that MeCP2 preferentially recruits the Sin3A-HDAC complex to PU.1 (Suzuki et al., 2003) . This result raised the possibility that Dnmt3s are also components of the large repressor complex of mSin3A-HDAC with PU.1. To clarify this point, we performed a pulldown assay using in vitro translated (IVT) recombinant forms of PU.1, MeCP2, mSin3A, HA-tagged HDAC1 and Dnmt3b. IVT-PU.1 and IVT-Dnmt3b were coimmunoprecipitated with IVT-HA-HDAC1 and IVT-mSin3A by an anti-HA Ab in the presence of IVT-MeCP2 (Figure 3, lane 9) . In vivo interaction between PU.1 and Dnmt3s. Immunoprecipitation analysis of PU.1 using goat polyclonal Ab against PU.1 (D-19; #sc-5949, Santa cruz) and normal rabbit IgG for detection of Dnmt3s. Each 1 mg of cell lysate from Sca-1 þ cells was immunoprecipitated with 1 mg of each Ab. The input was 1% of the total amount of protein used for immunoprecipitation. Western blot analysis was performed using the Ab against Dnmt3a (upper column) and Dnmt3b (middle column). As a control, each 10 mg of cell lysates for input was analysed by Ab against PU.1 (bottom column). The specific bands for Dnmt3a, Dnmt3b and PU.1 are indicated by an arrow. (b) In vitro interaction between PU.1 and Dnmt3s. In vitro translated 35 S-labeled luciferase, CBP1890, MeCP2, Dnmt3a and Dnmt3b were incubated with the 50% slurry of 20 ml of immobilized GST protein and GST-PU.1 fusion protein, and bound proteins were subjected to Nu-PAGE followed by autoradiography. Epigenetic transcriptional repression of PU.1-mediated reporter activity by Dnmt3s Several studies have shown that Dnmt3a and Dnmt3b are associated with HDAC1 and HDAC2 in vivo and in vitro (Robertson et al., 2000; Bachman et al., 2001; Fuks et al., 2001) . Histone deacetylase removes the acetyl groups from the amino-terminal of the histone tails, which triggers the assembly of a tightly packed chromatin inaccessible to the transcriptional machinery (Jenuwein and Allis, 2001) . These findings raised the possibility that both Dnmt3a and Dnmt3b affect the transcriptional activity of PU.1 as transcriptional corepressors through the formation of a complex with HDAC1. To address this possibility, we performed a luciferase reporter assay using artificial reporter constructs with or without trimerized PU.1-binding sites upstream of the thymidine kinase (TK) promoter, pTK100-PUx3-Luc and pTK-100-Luc. When the expression vector for PU.1 was transfected into HeLa cells with the pTK100-PUx3-Luc reporter, reporter activity increased about 13-fold ( Figure 4a ). When intact Dnmt3a or Dnmt3b was coexpressed with PU.1, the activity was repressed in a dose-dependent manner. Expression of PU.1 had no effect on the pTK100-Luc reporter, and expression of Dnmt3a or Dnmt3b alone did not affect the pTK100-PUx3-Luc or pTK100-Luc reporter construct (data not shown). These results suggest that Dnmt3a and Dnmt3b repress the PU.1-mediated transcriptional activation. Recent observations convinced us that the two major epigenetic gene-silencing mechanisms, the acetylation of histones and the methylation of DNA, are linked to S-labeled Dnmt3a (upper panel) and Dnmt3b (center panel) were incubated with the 50% slurry of 20 ml of immobilized GST protein and GST-fusion proteins containing various deletion mutants of PU.1, and bound in vitro-translated Dnmt3s were subjected to Nu-PAGE followed by autoradiography. The GST-PU.1 mutant proteins were subjected to Nu-PAGE, followed by Coomasie brilliant blue (CBB) staining. The proteins are indicated with asterisks (*) (lower panel). (c) A schematic diagram of various deletion mutants of Dnmt3a (upper) and Dnmt3b (lower) fused to GST. Numbers correspond to amino-acid positions in the Dnmt3 proteins. PWWP and ATRX indicate the regulatory domain and Cys-rich PHD homology domain of Dnmt3s, respectively. (d) GST pulldown assay using GST-Dnmt3s deletion mutants. In vitro-translated 35 S-labeled PU.1 was incubated with the 50% slurry of 20 ml of immobilized GST protein and GST-fusion proteins containing various deletion mutants of Dnmt3a (left panel) and Dnmt3b (right panel), and bound in vitro-translated PU.1 was subjected to Nu-PAGE, followed by autoradiography. GSTDnmt3s mutants were subjected to Nu-PAGE, followed by CBB staining. The proteins are indicated with asterisks (*).
PU.1-mediated transcriptional repression by DNA methylation M Suzuki et al each other (Okano et al., 1998) . We speculated that Dnmt3a-and Dnmt3b-mediated transrepression of pTK100-PUx3-Luc depends on their DNA methyltransferase activity and/or on the histone deacetylase activity through the formation of a complex with HDACs. To examine which is the case, a reporter assay was performed in the presence of 5-aza-deoxycitidine (5-AZAdC), a methyltransferase inhibitor, or trichostatin A (TSA), a histone deacetylase-specific inhibitor. HeLa cells were transfected with expression vectors for PU.1 and Dnmt3a or Dnmt3b, and with the reporter plasmid pTK100-PUx3-Luc or pTK100-Luc with 5AZAdC or TSA. Dnmt3a-and Dnmt3b-mediated transrepression was diminished when 5AZAdC, but not TSA, was added ( Figure 4b ). These results suggest that the transrepressional activity of Dnmt3a and Dnmt3b toward PU.1-mediated transcription is dependent on DNA methylation rather than histone deacetylation.
Colocalization of PU.1 and Dnmt3s at the PU.1-binding site of the pTK100-PUx3-Luc reporter To determine whether PU.1 and Dnmt3a or Dnmt3b colocalize at the PU.1-binding site in the chromatin molecules, we performed a chromatin immunoprecipitation (ChIP) assay. Expression vectors for PU.1 and the wild-type Dnmt3a or Dnmt3b were transfected with the reporter plasmid, pTK100-Luc or pTK100-PUx3-Luc, into 293T cells ( Figure 5 ). After immunoprecipitation, the target DNA sequence between the thymidine kinase (TK) promoter region and the luciferase (Luc) gene was amplified by PCR using specific primers for this region. The chromatin immunoprecipitates obtained with an Ab against PU.1 from all of the cells transfected with PU.1 alone or PU.1 and Dnmt3s were enriched for the chromatin containing the DNA sequence amplified by PCR when the pTK100-PUx3-Luc vector was used as a reporter ( Figure 5 , left column, lanes 2, 5 and 6). In contrast, the chromatin immunoprecipitates obtained with the Ab against FLAG from the cells transfected with PU.1 alone or PU.1 and Dnmt3s ( Figure 5 , left column, lanes 5 and 6), but not from the cells transfected with PU.1 alone and Dnmt3a or Dnmt3b alone, were enriched for the chromatin containing the DNA sequence amplified by PCR ( Figure 5 , left column, lanes 3 and 4). When pTK-100-Luc having no PU.1-binding site was transfected as a reporter, amplification of DNA was not detected in the chromatin immunoprecipitates obtained with either of the Abs ( Figure 5 , right column, S-labeled PU.1, Dnmt3b, MeCP2, mSin3A and HA-tagged HDAC1 were synthesized by TNT systems (Promega). Each in vitro translate was mixed as indicated. Input proteins corresponding to 10% of the total amount of proteins were used for immunoprecipitation and were spread by NuPAGE. The proteins are indicated with asterisks (*). Proteins immunoprecipitated with the Ab against HA were analysed by NuPAGE, followed by autoradiography.
PU.1-mediated transcriptional repression by DNA methylation M Suzuki et al lanes 7-12). These results indicate that Dnmt3a and Dnmt3b bind to and colocalize with PU.1 at the PU.1-binding site in the chromatin molecule.
Methylation status of the CpG sites in the pTK100xPUx3-Luc reporter with PU.1 and Dnmt3s
The above results strongly suggest that the formation of a complex between PU.1 and Dnmt3s represses the transcriptional activity by modulating DNA methylation in the promoter containing PU.1-binding sites. We therefore investigated the methylation status of pTK100-PUx3-Luc and pTK100-PUmut.x3-Luc cotransfected with or without PU.1 alone or PU.1 and Dnmt3s in HeLa cells. In all, 11 CpG sites exist in the minimal promoter of the TK gene. They are shown with vertical bars in the illustrations of the promoters in Figure 6 . Bisulfite sequence analysis revealed that most CpG sites of pTK100-PUx3-Luc were methylated in the cells expressing PU.1 and Dnmt3b, while the sites of pTK100-PUmut.x3-Luc were unmethylated ( Figure 6 , column 4). The CpG sites neighboring the PU.1-binding site in pTK100-PUx3-Luc were unmethylated in the Crosslinked cell lysates were prepared from 293T cells cotransfected with pTK-100-PU.1x3-Luc or pTK-100-Luc and the expression vector for PU.1 and/or FLAG-tagged Dnmt3a or Dnmt3b. Proteins immunoprecipitated with the Abs against PU.1, FLAG or acetylated histone H4 were de-crosslinked at 651C overnight. DNA from de-crosslinked chromatins from immunoprecipitates was amplifed by PCR using specific primers for the region between the TK-100 promoter and the luciferase gene.
PU.1-mediated transcriptional repression by DNA methylation M Suzuki et al absence of PU.1 ( Figure 6 , columns 2 and 3). These results suggest that overexpression of both PU.1 and Dnmt3b leads to methylation of the CpG sites neighboring the PU.1-binding sites in the pTK100-PUx3-Luc promoter. We next investigated the methylation status of CpG sites in pTK100-PUx3-Luc and pTK100-PUmut.x3-Luc after treatment with 5AZAdC. Addition of 1 mM 5AZAdC significantly reduced the number of methylated CpG sites in both pTK100-PUx3-Luc and pTK100-PUmut.x3-Luc in the cells expressing PU.1 and Dnmt3b (Figure 6 , lower column). Almost all of the CpG sites were unmethylated with the cells expressing PU.1 or Dnmt3a alone (data not shown). We obtained similar results by using Dnmt3a in place of Dnmt3b (data not shown). These results suggest that the methylation status of the promoter region of pTK100-PUx3-Luc is PU.1-and Dnmt3-dependent. p16 gene, a putative target gene controlled by PU.1 There are very few reports indicating that the repression of cell-type-specific gene expression is mediated by PU.1 (Hwang et al., 2004; Linderson et al., 2004) . Moreover, there is no report indicating that PU.1-mediated transcriptional repression is mediated by DNA hypermethylation. The promoter region of the p16 gene, a cyclin-dependent kinase inhibitor gene, has several Etsbinding sites (Ohtani et al., 2001 ) and many CpG sites (Figure 7a ). Therefore, we examined whether PU.1 regulates transcription of the p16 gene negatively through hypermethylation of the CpG site in the promoter. The activities of the reporter in which 5 0 sequential deletion derivatives of the p16 promoter were fused to the luciferase gene were examined in the presence or absence of PU.1 expression in HeLa cells that lack endogenous PU.1. The activity of the reporter containing 869 nucleotides upstream from the first ATG initiation codon, which has 10 Ets-binding sites, was reduced to about 60% when PU.1 was expressed (Figure 7b) . To verify the cis-element responsible for this PU.1-dependent repression, the promoter activities of the constructs containing 798, 703, 604, 530, 442 or 343 nucleotides upstream from the translation initiation site were investigated. The PU.1-dependent repression observed with the À343 construct was markedly reduced when PU.1 was expressed, although all of the constructs lost some activity under the conditions (Figure 7b , upper column). However, when a mutation was promoter locus. Crosslinked cell lysates were prepared from 293T cells cotransfected with the p16 promoter À343 construct-Luc reporter vector and an expression vector for PU.1 and/or FLAG-tagged Dnmt3a or Dnmt3b. Proteins from the 293T cells were immunoprecipitated using Abs against PU.1 or FLAG. Each DNA extracted from immunoprecipitated chromatin samples was amplified by PCR with p16 promoter-specific primers.
PU.1-mediated transcriptional repression by DNA methylation M Suzuki et al introduced in to the PU.1-binding site in the À343 construct (5 0 -GGAA-3 0 to 5 0 -AATT-3 0 at nucleotide position À105 to À102), the reduction in reporter activity decreased. These results suggest that the Etsbinding site containing the consensus recognition sequence 5 0 -GGAA-3 0 , nucleotide À105 to À102 from the first ATG codon, is responsible for the negative regulation of the p16 promoter activity by PU.1. In contrast to the p16 promoter, the activity of the M-CSF receptor promoter was accelerated with PU.1 expression (Figure 7b, lower column) , suggesting that PU.1-dependent transcriptional repression is promoter context-dependent.
To determine whether PU.1 binds to the potential Ets-binding site (À105 to À102 nt) in the p16 promoter, an electromobility shift assay (EMSA) was performed. In vitro translated PU.1 bound to the probe ( Figure 7C , lane 1). Moreover, a DNA-protein complex in the probes specifically disappeared when an Ab against PU.1 was added to the reaction mixture (Figure 7c , lane 4). These results suggest that PU.1 binds directly to the putative Ets-binding site in the p16 promoter.
To define whether PU.1 and Dnmt3s colocalized at the Ets-binding site of the p16 promoter, we performed ChIP assays using the p16 promoter À343 construct-Luc reporter vector. Expression vectors for PU.1 and FLAG-tagged Dnmt3a or Dnmt3b were cotransfected with the reporter into 293T cells. After immunoprecipitation, the target DNA sequence was amplified by PCR using specific primers between the p16 promoter region and the luciferase gene. In the ChIP assays, immunoprecipitates obtained with an Ab against PU.1 from the cells cotransfected with PU.1 and Dnmt3a or Dnmt3b were enriched for the chromatin containing the DNA sequence amplified by PCR (Figure 7d , top panel, lanes 4-6). Similarly, immunoprecipitates obtained with an Ab against FLAG from the cells cotransfected with PU.1 and Dnmt3a or Dnmt3b were enriched for the chromatin containing the DNA sequence amplified by PCR (Figure 7d , second panel, lanes 5 and 6). The DNA was not amplified on using the immunoprecipitate from the cells transfected with Dnmt3a or Dnmt3b alone (Figure 7d, lanes 2 and 3) . These results suggest that Dnmt3a and Dnmt3b colocalize with PU.1 at the Ets-binding site of the p16 promoter, similar to the results obtained with the pTK100-PUx3-Luc reporter gene.
On the basis of the above observations, it was suggested that PU.1 colocalized with Dnmt3s on the p16 promoter to repress the activity. To make this more clear, we next investigated whether expression of PU.1 leads to hypermethylation of the endogenous p16 promoter in NIH3T3.
At first, we introduced an expression vector of the PU.1 gene or an empty vector into NIH3T3 cells, and several clones were obtained by subsequent geneticin (G418) selection. Western blot analysis showed that a clone expressed a moderate level of PU.1 and another clone expressed a high level of PU.1 in comparison to the controls (NIH3T3(À)), which were transfected with the empty vector. They were designated NIH3T3/ PU.1M and NIH3T3/PU.1H (Figure 8a, lanes 2  and 3) .
Using these clones, we next investigated the expression levels of the p16, p19, p21, p27 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes by RT-PCR (Figure 8b ). The levels of p16 and p27 transcripts were markedly reduced in both NIH3T3/PU.1M and NIH3T3/PU.1H cells as compared with NIH3T3 cells. The levels of p19 and p21 transcripts were invariable among NIH3T3(À), NIH3T3/PU.1M and NIH3T3/ PU.1H cells (Figure 8b ). This observation supported the notion that PU.1 represses not only p16 but also p27 gene expression.
Next, we examined the methylation status of mouse p16 promoter regions in NIH3T3(À) and NIH3T3/ PU.1H cells using bisulfite sequence. Although the p16 promoter sequences are not well conserved between mice and humans, the mouse p16 promoter has potential Ets-binding sites (Figure 7c ). Wide-ranging CpG sites (nucleotide À480 to À18 from the first ATG) of the mouse p16 promoter were subjected to bisulfite sequence analysis. No methylation of p16 promoter was observed in NIH3T3 cells. In contrast, in NIH3T3/PU.1H cells, 74% (78/90 sites) of all conserved CpGs were methylated. These observations suggest that PU.1 contributes to the site-specific methylation of the p16 promoter in vivo.
To investigate whether a direct interaction between PU.1 and Dnmt3s is involved in DNA methylation in the p16 promoter, we carried out that ChIP assay. As shown in Figure 8d , the immunoprecipitates from NIH3T3/PU.1M and NIH3T3/PU.1H cells, but not from NIH3T3(À) cells, with Abs against PU.1 and Dnmt3a and Dnmt3b enriched for the chromatincontaining p16 promoter region sequence were amplified by PCR (À548 to À2 nt from first ATG). These results strongly suggest that Dnmt3s are involved in the CpG methylation of the p16 promoter region through direct interaction with PU.1.
Discussion
Among the three DNA methyltransferases (Dnmts) isolated to date, Dnmt1 and Dnmt3a/Dnmt3b, the former has been shown to function as a maintenance methylase and the latter two as de novo DNA methylases (Robertson 2001 ). All of them have been shown to interact directly with the mSin3A-HDACs complex (Robertson et al., 2000; Rountree et al., 2000; Fuks et al., 2001; Datta et al., 2003) . In this study, we have revealed that Dnmt3a and Dnmt3b are novel partners of the Ets family transcription factor PU.1. To understand the molecular basis of the association between PU.1 and Dnmt3s, we determined their binding domains by using various deletion mutants. PU.1 interacted directly with the ATRX domain of Dnmt3a and Dnmt3b via the Ets domain. The Ets domain of PU.1 is also necessary for interaction with MeCP2, as shown in our previous study (Suzuki et al., 2003) . However, there was no competition between Dnmt3s and MeCP2 for binding to PU.1 (Figure 3) . Rather, the binding of Dnmt3b to the complex containing PU.1 and mSin3A/HDAC appeared to be MeCP2-dependent.
Since Dnmt3s were coimmunoprecipitated with PU.1, the PU.1-Dnmt3s complex (Figure 3 ) may be involved in the regulation of not only the chromatin structure but also site-specific DNA methylation. A recent study has revealed that the epigenetic modifications of DNA and chromatin, such as methylation, acetylation, phosphorylation and ubiquitination, are closely related to a variety of biological processes such as gene expression, tumorigenesis and cell differentiation (Singal and Ginder, 1999) . Histone acetylation/deacetylation and DNA methylation are the best-known examples of epigenetic modification. Previously, we showed that binding of MeCP2 to PU.1 may facilitate the formation of a complex with mSin3A and HDAC1, and PU.1 may downregulate its target genes through the deacetylation of histone (Suzuki et al., 2003) . We reported here that the PU.1-Dnmt3s complex repressed the promoter activity of pTK100-PUx3-Luc (Figure 4a) . Furthermore, we demonstrated that this downregulation was caused by DNA methylation rather than histone deacetylation, judging from the experimental finding that transcriptional repression by PU.1-Dnmt3s diminished in the presence of 5AZAdC, an inhibitor of DNA methyltransferase, but not TSA, an inhibitor of histone deacetylase (Figure 4b ). These results suggest that the repression of the promoter activity by the PU.1-Dnmt3s complex is dependent on DNA methylation, but seems to be independent of histone deacetylation. It is still unclear whether the PU.1-MeCP2-mediated downregulation of transcription by histone deacetylation and Crosslinked cell lysate was prepared from NIH3T3(À), NIH3T3/PU.1M and NIH3T3/PU.1H cells. Cell lysates were immunoprecipitated by Abs against PU.1, Dnmt3a or Dnmt3b. As a negative control, cell lysates were immunoprecipitated by rabbit IgG. Each DNA extracted from immunoprecipitated chromatin samples was amplified by PCR with p16 promoter-specific primers as mentioned in Materials and methods. As a positive control, chromatin DNA was extracted from NIH3T3(À), NIH3T3/PU.1M and NIH3T3/PU.1H cells and amplified by PCR with p16 promoter-specific primers.
PU.1-mediated transcriptional repression by DNA methylation M Suzuki et al PU.1-Dnmt3s-mediated downregulation of transcription by DNA methylation occur simultaneously in the same promoter. PU.1 was originally characterized as a transcriptional activator during hematopoietic differentiation (Tenen et al., 1997; Oikawa and Yamada, 2003) . Our initial study indicated that PU.1 interacts with CBP/p300 for transcriptional activation . We also found that PU.1 acts as a transcriptional repressor by associating with mSin3A and HDAC1 (KiharaNegishi et al., 2001) . The association of PU.1 with mSin3A and HDACs was recently confirmed by others examining the transcriptional regulation of the mouse m opioid receptor gene (Hwang et al., 2004) . We also reported that MeCP2 acts as a corepressor of PU.1, probably by facilitating the formation of a complex with mSin3A and HDACs (Suzuki et al., 2003) . In this report, we showed that PU.1 modulates the DNA methylation neighboring PU.1-binding sites by associating with Dnmt3s. Five out of 11 CpG sites neighboring the PU.1-binding sites in pTK100-PUx3-Luc were methylated with both PU.1 and Dnmt3s ( Figure 6 ). We do not know the exact reason why the other six CpG sites neighboring the transcriptional start site were methylated notwithstanding the presence of PU.1 and/ or Dnmt3s. It is likely that demethylation of the CpG sites in the nucleosome occurs after PU.1-CBP complex formation.
The involvement of the complex formed between transcription factors and Dnmts in DNA methylation is little understood. The report that a complex of the PML-RAR fusion protein and Dnmts contributes to hypermethylation of the RARb2 promoter to silence the gene expression is the first example of site-specific DNA methylation (Croce et al., 2002) . To our knowledge, our result that PU.1-Dnmt3s complex formation contributed to hypermethylation of the p16 INK4A promoter in NIH3T3/PU.1 cells, expressing exogenous PU.1, is the second example. PU.1 may be a regulator of p16 and p27 gene expression in PU.1-expressing cells and may contribute to cell growth through epigenetic modulation. In contrast to expressions of p16, expressions of p19 and p21 were not downregulated by PU.1. Our results suggest that these genes are differently regulated, although Ets-binding sites exist in the promoters of both genes.
Overexpression and graded reduction of PU.1 induce erythroleukemia and myeloid leukemia in mice, respectively (Moreau-Gachelin et al., 1996; Rosenbauer et al., 2004) . Furthermore, an aberrant expression of PU.1 is associated with the development of myeloid leukemia in humans (Muller et al., 2002; Vangala et al., 2003) . Therefore, it is tempting to speculate that the deregulated expression of PU.1 contributes to leukemogenesis through the deregulation of p16 and p27 expression, but not p19 and p21 expression. Alternatively, large amounts of PU.1 might sequester Dnmts and subsequently lead to aberrant DNA methylation. In this connection, it has been reported that knockout mice deficient in Dnmt1 are prone to developing malignant tumors (Walsh and Bestor, 1999) .
Post-translational modifications of PU.1 such as phosphorylation, methylation and acetylation may be involved in the preferential recruitment of coactivators such as CBP, or corepressors such as mSin3A, MeCP2 and Dnmts, since there is much evidence that the posttranslational modification of histone proteins and transcription factors plays an important role in the regulation of gene expression. The possible involvement of post-translational modification of PU.1 in the selection of cofactors for binding remains to be examined in future. Whether PU.1 is associated with the coactivator complex or the corepressor complex might depend on the promoter DNA and the binding of other transcription factors that cooperate with or antagonize PU.1.
Materials and methods

Cell culture
All the cells used in this study were maintained at 371C under 5% CO 2 in Dulbecco's modified Eagle's minimum essential medium (DMEM) supplemented with 10% fetal calf serum. The NIH3T3/PU.1 cells, NIH3T3 cells transfected with a PU.1 expression vector, were selected in a medium containing 800 mg/ml of G418 (Wako).
Isolation of bone marrow precursor populations
The murine hematopoietic progenitor (Sca-1 þ ) cells were prepared from bone marrow (1 Â 10 8 ) cells. The Sca-1 þ cells were purified using the anti-Sca-1 microbeads and magnetic columns (Miltenyi Biotec) according to the manufacturer's instructions.
Construction of vectors
Full-length mouse Dnmt3a and Dnmt3b cDNAs were obtained by RT-PCR from mouse erythroleukemia (MEL) cells using the following primers: forward-3a4 (from Dnmt3a nt 4-23); 5 0 -GGATCCGACACCAGCAGCTCCTCTC-3 0 (BamHI site is underlined) and reverse-3a2727 (from Dnmt3a nt 2706-2727), 5 0 -CTCGAGTTACACACAAGCAAAATA TTCC-3 0 (XhoI site is underlined); and forward-3b4 (from Dnmt3b nt 4-23), 5 0 -GGATCCAAGGGAGACAGCAGA CATCTG-3 0 (BamHI site is underlined) and reverse-3b2331 (from Dnmt3b nt 2331-2312), 5 0 -CTCGAGCTATTCACA GGCAAAGTAGTC-3 0 (XhoI site is underlined). The PCR products were digested with BamHI and XhoI, and were subcloned in frame into a pCMV-FLAG-vector (Stratagene) or a pCMV-HA-vector using the BamHI and XhoI sites.
The expression vectors of GST-fusion proteins were constructed by subcloning the Dnmt3a and Dnmt3b cDNA fragments in frame into the vector pGEX4T-1 (Amersham Bioscience). The cDNA fragments for Dnmt3a deletion mutants were obtained by RT-PCR using the following primers: forward-3a4 as indicated above, forward-3a1027 (from nt 1027-1046); 5 0 -CGGGATCCCTGAGCTCCTTCT GCAGTGC-3 0 (BamHI site is underlined), forward-3a1888 (from nt , and 5 0 -CGGGATCCATCCGCGTGCT GTCTCTCTTT-3 0 (BamHI site is underlined), reverse-3a1887 (from nt 1868-1887); 5 0 -GGGCTCGAGGGGCTTCCTCTT CTCAGCT-3 0 XhoI site is underlined), reverse-3a1026 (from nt 1007-1026); 5 0 -GGGCTCGAGCGGCATGAGCTTCTC CACAC-3 0 (XhoI site is underlined).
Dnmt3a-N was obtained by using forward-3a4 and reverse-3a1026, Dnmt3a-ATRX by using forward-3a1027 and reverse-3a1887, and Dnmt3a-C by using forward-3a1888 and reverse-3a2727.
The cDNA fragments for Dnmt3b deletion mutants were obtained in the same way using the following primers: forward-3b4 as indicated above, forward-3b901 (from nt 901-921), and 5 0 -CGGGATCCCTGAGCTCCTTCTGCA GTGC-3 0 (BamHI site is underlined), forward-3a1601 (from nt 1601-1620); 5 0 -CGGGATCCATCCGCGTGCTGTCTC TCTTT-3 0 (BamHI site is underlined), reverse-3b1600 (from nt 1581-1600); 5 0 -GGGCTCGAGGGGCTTCCTCTTCT CAGCT-3 0 (XhoI site is underlined), reverse-3b900 (from nt 881-900), and 5 0 -GGGCTCGAGCGGCATGAGCTTCTC CACAC-3 0 (XhoI site is underlined). Dnmt3b-N was obtained by using forward-3b4 and reverse3b900, Dnmt3b-ATRX by using forward-3b901 and reverse3b1600, and Dnmt3b-C by using forward-3b1601 and reverse3b2331. The deletion mutants were also subcloned into pCMV-FLAG-vector, pCMV-HA-vector or pGEX4T-1. All cloned PCR products were verified to have sequences that had no additional mutations. The expression vector for HA-tagged PU.1 was obtained by subcloning of the PU.1 gene from pCMV-FLAG-PU.1 that we made previously .
In vitro transcription and translation
In vitro transcription and translation were carried out by using T3 RNA polymerase and rabbit reticulocyte lysate (TNT quick-coupled transcription/translation system; Promega Bioscience, Inc.) in accordance with the supplier's directions. In vitro translates were labeled with 35 S-methionine (Amersham #AG1094).
Immunoprecipitation and immunoblotting
Cell lysates were prepared as described previously . Immunoprecipitation and immunoblotting were performed as we reported , with minor modifications. Briefly, 1 mg of each cell lysate from hematopoietic progenitor (Sac-1 þ ) cells was immunoprecipitated with 1 mg of Ab. Each immunoprecipitate was separated with a 4-12% Nu-PAGE 3-morpholinopropanesulfonic acid (MOPS) system (Invitrogen) and then transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore) by semi-dry blotting. Western blotting was performed using standard procedures and visualized using ECL-PLUS (Amersham). For immunoprecipitation, goat polyclonal Ab against PU.1 (D-19; #sc-5949, Santa Cruz) was used. For immunoblotting, rabbit polyclonal Abs against Dnmt3a (H-295; #sc-20703, Santa Cruz) and against Dnmt3b (H-230; #sc-20704, Strata cruz) were used.
GST pulldown assay GST fusion proteins were expressed in Escherichia coli DH5a and purified according to the manufacturer's directions (Amersham Bioscience). In all, 10 mg of GST or GST fusion proteins immobilized to Glutathione-Sepharose beads. The beads were washed extensively in a binding buffer (10 mM 2-amino-2-hydroxymethyl-1,3-propanediol (Tris), pH 7.4, 1 mM ethylenediamine-N, N, N 0 , N 0 -tetraacetic acid (EDTA), 150 mM NaCl, 1% Triton X-100, 1% Nodiet P-40 (NP-40) and 0.1% SDS supplemented with 0.1 mM phenylmethylsulfonyl fluoride (PMSF) and 0.1 mM sodium vanadate as protein inhibitors) and incubated with 10 ml of 35 S-labeled in vitro translates generated as above for 4 h at 41C. The beads that bound proteins were washed four times with binding buffer boiled for 2 min in 10 ml of 2Â SDS sample buffer, and separated using 4-12% Nu-PAGE MOPS systems (Invitrogen). The precipitates were detected by autoradiography.
Luciferase assay
Cell extracts for the luciferase assay were prepared as described previously . Vectors for the reporter gene, pTK100-Luc and pTK-100-PUx3-Luc, and an expression vector, pEF-PU.1, were constructed as described previously . The various deletion mutants of p16 promoter-Luc vector constructs have been described previously (Hara et al., 1996) .
pCMV-FLAG-Dnmt3a and pCMV-FLAG-Dnmt3b were constructed as described above. The reporter vector and effecter vectors 0.1 mg each were cotransfected into HeLa cells cultured in 24-well plates. Luciferase activity was assayed with 5 ml of protein in the cell lysate and 100 ml of Pikka-gene substrate (Nippongene) with a luminometer (Berthold, LB9501).
RT-PCR
Total RNA was extracted from 1 Â 10 7 cells, and first-strand cDNA was obtained by incubation of 1 mg of total RNA with oligo dT and reverse transcriptase (Superscript III, Invitrogen) according to the manufacturer's directions.
PCR was performed using 1 ml of the RT products with Ampli-Taq polymerase (Applied Biosystems). In all, 25-40 cycles of amplification were carried out with the following profile for each cycle: denaturating at 941C for 1 min, annealing at 551C for 1 min and extension at 721C for 1 min. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. The primers used were as follows: mouse GAPDH forward; 5 0 -CCAAGGTCATCCATGACA AC-3 0 , reverse 5 0 -CTGTTGCTGTAGCCGTATTC-3 0 , mouse p16 forward; 5 0 -ATGGGTCGCAGGTTCTT-3 0 , reverse 5 0 -TGAGCTGAAGCTATGCCCG-3 0 , mouse p19 forward; 5 0 -ATGGAGTCCGCTGCAGACAG-3 0 , reverse; 5 0 -TTAGCTC TGCTCTTGGGATTG-3 0 , mouse p21 forward; 5 0 -GTGGTA CTTGTGAGCCAAGG-3 0 , reverse; 5 0 -CACAGAGCTGAT GCACGTCCTCGAT-3 0 ), mouse p27 Forward; 5 0 -ATGT-CAAACGTGAGAGTGTC, reverse; 5 0 -TTACGTCTGGCG TCGAAGGC-3 0 , mouse PU.1 forward; 5 0 -CACAGAGCT GATGCACGTCCTCGAT-3 0 , reverse; and 5 0 -CGGGAT CCGTCTCTGCGGGCGATCAGTG-3 0 . The PCR products were electrophoresed in 1% agarose gels in 1 Â TBE buffer containing ethidium bromide.
Chromation immunoprecipitation (ChIP) assay
ChIP assays were performed as described previously (Suzuki et al., 2003) , with minor modifications. Abs against PU.1, against FLAG, against acethylated histone H4, against Dnmt3a and against Dnmt3b were used for immunoprecipitation. Precipitated protein-DNA complexes were washed twice with a low-salt buffer (20 mM Tris-HCl (pH 8.1), 2 mM EDTA, 150 mM NaCl, 0.1% SDS and 1% Triton-X100), a high-salt buffer (20 mM Tris-HCl (pH 8.1), 2 mM EDTA, 500 mM NaCl, 0.1% SDS and 1% Triton-X100), LiCl buffer (10 mM Tris-HCl (pH 8.1), 1 mM EDTA, 250 mM LiCl, 1% NP40 and 1% sodium deoxycholate (DOC)) and 1 Â TE buffer. The precipitated proteins including DNA were dissolved in 1 Â TE buffer and incubated at 651C overnight to reverse crosslinks. Following RNase A, proteinase K, phenol/chloroform extraction and ethanol precipitaion, the samples were subjected to 40 cycles of PCR amplification. The primers for detection of the p16 promoter-Luc construct were as follows: forward (human p16 promoter region at À120 to À101) 5 0 -TCCGCCAG PU.1-mediated transcriptional repression by DNA methylation M Suzuki et al CACCGGAGGAAG-3 0 , reverse (luciferase cDNA region at 345 to 364) 5 0 -GCGAAATGCCCATACTGTTTG-3 0 . The primers for detection of the mouse p16 promoter were as follows: forward (mouse p16 promoter region at À532 to 511) 5 0 -tgatgcaaaattaccctccttc-3 0 , reverse (mouse p16 promoter region at À20 to À1) 5 0 -GGAGAGCCATCTGGAGCA GC-3 0 .
Electromobility shift assay (EMSA)
The double-strand oligonucleotide for EMSA (human p16 promoter at À110 to À81: 5 0 -GGTTGTATCGCGGAGGAA GGAAACGGGGCG-3 0 ) was radiolabeled with [g-32 P]ATP. EMSAs were performed in 20 ml of binding buffer (20 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES) (pH 7.9), 0.1 M KCl, 5 mM MgCl 2 , 2 mM EDTA, 1 mM DTT and 20% (vol/vol) glycerol) containing 1 mg of poly (dIdC) Á poly (dI-dC), 0.5 fmol (approximately 5 Â 10 3 c.p.m.) of 32 P-labeled oligonucleotide, 1 mg of each Ab and 1 ml of in vitrotranslated PU.1. DNA-protein complexes were resolved by electrophoresis on 5% polyacrylamide gels at 41C in TGE buffer (25 mM Tris-HCl (pH 8.0), 192 mM glycine and 2 nM EDTA). The gels were dried and autoradiographed by X-ray films at À801C.
Bisulfite sequence analysis
The method of bisulfite treatment has been explained previously (Herman et al., 1996) . Genomic DNA was extracted from HeLa cells and NIH3T3 cells by using ISOGENE (Nippongene Inc.). In all, 10 mg of genomic DNA was digested with XbaI and denatured in 0.3 M NaOH for 15 min at 371C in 100 ml, and then 60 ml of 10 mM hydoroquinone and 1 ml of 3.6 M sodium bisulfite (pH 5.0) were added. The reaction mixture was incubated at 501C for 3 h and at 961C for 3 min for five cycles. The DNA was purified with a desalting column (Wizard DNA clean-up kit; Promega). NaOH was added to a final concentration of 0.3 M, incubated at 371C for 15 min, neutralized by adding 3 M ammonium acetate, precipitated with ethanol, dried and resuspended in 100 ml of water. An aliquot of genomic DNA was amplified using cytosine deamination-specific primers. The methyl-specific PCR products were ligated into pGEM-T easily using the TA cloning kit (Promega). In all, 10 clones from each sample were sequenced in both directions. For bisulfite sequences of the mouse p16 promoter, p16f-Bi (mouse p16 promoter at nt À502 to À481), 5 0 -AATATTTGGGTGTTGTATTGGG-3 0 , and p16r-Bi (at À17 to þ 7), 5 0 -ACTCCATACTACTCCAAA TAACTC-3 0 were designed.
Abbreviations
GST, glutathione-S-transferase; G418, geneticin; Tris, 2-amino-2-hydroxymethyl-1,3-propanediol; DMEM, Dulbecco's modified Eagle's minimum essential medium; HEPES, 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid; MOPS, 3-morpholinopropanesulfonic acid; PVDF, polyvinylidene fluoride; PMSF, phenylmethylsulfonyl fluoride; EDTA, ethylenediamine-N, N, N 0 , N 0 -tetraacetic acid; SDS, sodium dodecylsulfate; DOC, sodium deoxycholate; NP-40, Nodiet P-40; 5-AZAdC, 5-aza-deoxycitidine; TSA, trichostatin A; HDAC, histone deacetyl transferase; CBP, CRE-binding protein; Dnmt, DNA methyltransferase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
